All News

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

I’ve experienced fatigue from cancer before but contracting COVID-19 took it to a whole other level.

Unreliable public transportation or limited access to a working vehicle may lead to delays in important follow-up care for cancer survivors.

Recent headlines have been highlighting a monoclonal antibody that eliminated evidence of disease in patients with rectal cancer, but I believe that findings from the research need to be taken with a few grains of caution.

Although there is little relief available to cancer survivors experiencing neuropathy, hope may be on the horizon.

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

As part of its Heal at Home series, CURE® worked with a registered dietitian from Georgetown Lombardi Comprehensive Cancer Center to put together several cancer-friendly dishes that everyone can enjoy this summer.

Before being diagnosed with cancer, I would turn my gaze away from people who were suffering, but now, I connect with them, and know that it could be me.

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

Patients quickly bond with Tiffany Beeler Vaughan, B.S.N., RN because they sense her strong empathy and compassion toward them, traits that are difficult to teach.

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Cancer and its treatments can affect oral health, though when I was diagnosed with breast cancer, the thought of seeing the dentist slipped my mind.

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population.

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

One of the most loving things I can do for my family is to purchase life insurance, but my application was turned down, presumably because of my cancer history.

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

Getting other medical opinions for my cancer diagnosis not only saved my life but also taught me self-care.

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.